Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2012

Organization, Basis of Presentation, and Summary of Select Significant Accounting Policies [Abstract]

BioTime's ownership of outstanding shares of its subsidiaries

Principles of consolidation – BioTime's condensed consolidated financial statements include the accounts of its subsidiaries. The following table reflects BioTime's ownership of the outstanding shares of its subsidiaries.

Subsidiary	BioTime Ownership	Country
ReCyte Therapeutics, Inc. (formerly Embryome Sciences, Inc.)	95.15%	USA
OncoCyte Corporation	75.3%	USA
OrthoCyte Corporation	100%	USA
ES Cell International Pte. Ltd.	100%	Singapore
BioTime Asia, Limited	81%	Hong Kong
Cell Cure Neurosciences Ltd.	53.6% (1)	Israel
LifeMap Sciences, Inc.	77.1% (2)	USA
LifeMap Sciences, Ltd.	(3)	Israel
BioTime Acquisition Corporation	96.7%	USA

(1)

Cell Cure Neurosciences has agreed to issue additional ordinary shares to BioTime in exchange for BioTime common shares which will increase BioTime's ownership, directly and through ESI, to approximately 62.6%. See Note 11.

(2)

LifeMap Sciences, Inc. has agreed to issue additional shares of its common stock to certain investors which will reduce BioTime's ownership 73.2%. See Note 9.

(3)

LifeMap Sciences, Ltd. is a wholly-owned subsidiary of LifeMap Sciences, Inc.

- Definition

The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.

+ References+ Details